Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as an oral formulation for oral use. It works by inhibiting lymphocyte proliferation, thereby reducing the risk of organ rejection in patients who have undergone solid‑organ transplantation. The medication meets European Union regulatory standards and is produced under stringent quality‑assurance protocols.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide, with reliable logistics and regulatory support.

Myfortic is an immunosuppressant used to prevent rejection in solid‑organ transplant recipients.

- Kidney transplant: helps maintain graft function by suppressing immune response. - Liver transplant: reduces incidence of acute rejection episodes. - Heart transplant: supports long‑term graft survival through lymphocyte inhibition. - Pancreas transplant: contributes to stable graft function and lowers rejection risk.

Myfortic may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Headache: mild cranial discomfort. - Infections: increased susceptibility to bacterial, viral or fungal infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count leading to fatigue. - Malignancy: rare increased risk of certain cancers.

When prescribing Myfortic, clinicians should observe several safety measures to minimize risks.

- Monitor blood counts: regular CBC testing to detect leukopenia or anemia. - Assess renal function: dose adjustments may be needed in impaired kidneys. - Avoid live vaccines: increased infection risk makes live attenuated vaccines contraindicated. - Counsel on infection signs: patients should report fever, cough, or unusual symptoms promptly. - Pregnancy and breastfeeding: use only if benefits outweigh risks; discuss with healthcare provider. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Myfortic can interact with several medicines, affecting its absorption or toxicity.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce mycophenolic acid absorption. - Cyclosporine: synergistic immunosuppression increases infection risk. - Tacrolimus: combined use may heighten mycophenolic acid exposure and toxicity.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, lowering drug levels. - Cholestyramine: binds drug in gut, decreasing effectiveness.